TRIAMTERENE AND HYDROCHLOROTHIAZIDE

Triamterene And Hydrochlorothiazide Adverse Events Reported to the FDA Over Time

How are Triamterene And Hydrochlorothiazide adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Triamterene And Hydrochlorothiazide, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Triamterene And Hydrochlorothiazide is flagged as the suspect drug causing the adverse event.

Most Common Triamterene And Hydrochlorothiazide Adverse Events Reported to the FDA

What are the most common Triamterene And Hydrochlorothiazide adverse events reported to the FDA?

Completed Suicide	52 (3.28%)
Dizziness	48 (3.02%)
Hyponatraemia	32 (2.02%)
Renal Failure Acute	32 (2.02%)
Dyspnoea	27 (1.7%)
Drug Ineffective	26 (1.64%)
Muscle Spasms	23 (1.45%)
Asthenia	21 (1.32%)
Pulmonary Embolism	20 (1.26%)
Hypotension	19 (1.2%)
Nausea	19 (1.2%)
	Show More
Diarrhoea	18 (1.13%)
Rash	18 (1.13%)
Hyperkalaemia	16 (1.01%)
Cardiac Arrest	15 (.95%)
Fatigue	14 (.88%)
Feeling Abnormal	14 (.88%)
Malaise	14 (.88%)
Pruritus	14 (.88%)
Reaction To Drug Excipients	14 (.88%)
Respiratory Arrest	14 (.88%)
Oedema Peripheral	13 (.82%)
Weight Decreased	13 (.82%)
Alopecia	12 (.76%)
Heart Rate Irregular	12 (.76%)
Hypokalaemia	12 (.76%)
Vomiting	12 (.76%)
Fall	11 (.69%)
Oedema	11 (.69%)
Blood Sodium Decreased	10 (.63%)
Condition Aggravated	10 (.63%)
Drug Interaction	10 (.63%)
Product Quality Issue	10 (.63%)
Product Substitution Issue	10 (.63%)
Urticaria	10 (.63%)
Blood Creatinine Increased	9 (.57%)
Blood Potassium Decreased	9 (.57%)
Dry Mouth	9 (.57%)
Headache	9 (.57%)
Heart Rate Increased	9 (.57%)
Muscular Weakness	9 (.57%)
Palpitations	9 (.57%)
Weight Increased	9 (.57%)
Constipation	8 (.5%)
Cough	8 (.5%)
Dehydration	8 (.5%)
Hypersensitivity	8 (.5%)
Hypovolaemia	8 (.5%)
Medication Error	8 (.5%)
Syncope	8 (.5%)
Abdominal Pain Upper	7 (.44%)
Back Pain	7 (.44%)
Burning Sensation	7 (.44%)
Cardio-respiratory Arrest	7 (.44%)
Cerebrovascular Accident	7 (.44%)
Chest Pain	7 (.44%)
Hyperhidrosis	7 (.44%)
Insomnia	7 (.44%)
Nephrolithiasis	7 (.44%)
Pain	7 (.44%)
Urine Output Decreased	7 (.44%)
Blood Pressure Decreased	6 (.38%)
Blood Urea Increased	6 (.38%)
Confusional State	6 (.38%)
Drug Dispensing Error	6 (.38%)
Drug Hypersensitivity	6 (.38%)
Dysgeusia	6 (.38%)
Erythema	6 (.38%)
Fluid Retention	6 (.38%)
Hypertension	6 (.38%)
Incorrect Dose Administered	6 (.38%)
Myalgia	6 (.38%)
Myocardial Infarction	6 (.38%)
Orthostatic Hypotension	6 (.38%)
Pneumonia	6 (.38%)
Rash Papular	6 (.38%)
Swelling	6 (.38%)
Therapeutic Response Unexpected Wit...	6 (.38%)
Abdominal Distension	5 (.32%)
Abdominal Pain	5 (.32%)
Atrial Fibrillation	5 (.32%)
Blood Pressure Increased	5 (.32%)
Cytolytic Hepatitis	5 (.32%)
Diabetes Mellitus	5 (.32%)
Disorientation	5 (.32%)
Drug Effect Decreased	5 (.32%)
Dysuria	5 (.32%)
Joint Swelling	5 (.32%)
Lethargy	5 (.32%)
Loss Of Consciousness	5 (.32%)
Mental Status Changes	5 (.32%)
Paraesthesia	5 (.32%)
Rash Pruritic	5 (.32%)
Somnolence	5 (.32%)
Swelling Face	5 (.32%)
Vision Blurred	5 (.32%)
Visual Acuity Reduced	5 (.32%)
Bowel Movement Irregularity	4 (.25%)
Bradycardia	4 (.25%)
Chills	4 (.25%)
Death	4 (.25%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Triamterene And Hydrochlorothiazide, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Triamterene And Hydrochlorothiazide is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Triamterene And Hydrochlorothiazide

What are the most common Triamterene And Hydrochlorothiazide adverse events reported to the FDA?

Neurological	102 (6.43%)
Electrolyte And Fluid Balance Condi...	89 (5.61%)
Epidermal And Dermal Conditions	76 (4.79%)
Respiratory	61 (3.84%)
Gastrointestinal Signs	60 (3.78%)
Therapeutic And Nontherapeutic Effe...	57 (3.59%)
Suicidal And Self-injurious Behavio...	55 (3.47%)
Cardiac Arrhythmias	46 (2.9%)
Renal Disorders	44 (2.77%)
Cardiac And Vascular Investigations	43 (2.71%)
Muscle	41 (2.58%)
	Show More
Gastrointestinal Motility And Defec...	37 (2.33%)
Medication Errors	35 (2.21%)
Allergic Conditions	31 (1.95%)
Decreased And Nonspecific Blood Pre...	31 (1.95%)
Renal And Urinary Tract Investigati...	29 (1.83%)
Urinary Tract Signs	27 (1.7%)
Water, Electrolyte And Mineral	27 (1.7%)
Musculoskeletal And Connective Tiss...	25 (1.58%)
Product Quality Issues	25 (1.58%)
Skin Appendage Conditions	23 (1.45%)
Physical Examination Topics	22 (1.39%)
Injuries	20 (1.26%)
Pulmonary Vascular	20 (1.26%)
Hepatic And Hepatobiliary	14 (.88%)
Appetite And General Nutritional	13 (.82%)
Joint	13 (.82%)
Angiedema And Urticaria	12 (.76%)
Cardiac Disorder Signs	11 (.69%)
Deliria	11 (.69%)
Headaches	11 (.69%)
Metabolic, Nutritional And Blood Ga...	11 (.69%)
Bone And Joint Injuries	10 (.63%)
Central Nervous System Vascular	10 (.63%)
Infections - Pathogen Unspecified	10 (.63%)
Salivary Gland Conditions	10 (.63%)
Vision	10 (.63%)
Chemical Injury And Poisoning	9 (.57%)
Coronary Artery	9 (.57%)
Hepatobiliary	9 (.57%)
Oral Soft Tissue Conditions	9 (.57%)
Sleep Disorders	9 (.57%)
Anxiety Disorders	8 (.5%)
Mental Impairment	8 (.5%)
Psychiatric	8 (.5%)
Urolithiases	8 (.5%)
Lower Respiratory Tract Disorders	7 (.44%)
Glucose Metabolism Disorders	6 (.38%)
Peripheral Neuropathies	6 (.38%)
Vascular Hypertensive	6 (.38%)
Hypothalamus And Pituitary Gland	5 (.32%)
Inner Ear And Viiith Cranial Nerve	5 (.32%)
Vascular	5 (.32%)
Acid-base	4 (.25%)
Anemias Nonhemolytic And Marrow Dep...	4 (.25%)
Fatal Outcomes	4 (.25%)
Gastrointestinal Stenosis And Obstr...	4 (.25%)
Heart Failures	4 (.25%)
Mood Disorders	4 (.25%)
Platelet	4 (.25%)
Reproductive Tract	4 (.25%)
Sleep Disturbances	4 (.25%)
Urethral Disorders	4 (.25%)
Bacterial Infectious	3 (.19%)
Bronchial Disorders	3 (.19%)
Cornification And Dystrophic Skin	3 (.19%)
Exocrine Pancreas Conditions	3 (.19%)
Gallbladder	3 (.19%)
Gastrointestinal Hemorrhages	3 (.19%)
Hearing	3 (.19%)
Hematology Investigations	3 (.19%)
Movement Disorders	3 (.19%)
Seizures	3 (.19%)
Somatoform And Factitious	3 (.19%)
Toxicology And Therapeutic Drug Mon...	3 (.19%)
Bile Duct	2 (.13%)
Body Temperature Conditions	2 (.13%)
Bone Disorders	2 (.13%)
Depressed Mood Disorders	2 (.13%)
Embolism And Thrombosis	2 (.13%)
Endocrine Gland Therapeutic Procedu...	2 (.13%)
Enzyme	2 (.13%)
Injuries By Physical Agents	2 (.13%)
Lifestyle Issues	2 (.13%)
Neuromuscular	2 (.13%)
Protein And Chemistry Analyses	2 (.13%)
Purine And Pyrimidine Metabolism	2 (.13%)
Red Blood Cell	2 (.13%)
Skin Vascular Abnormalities	2 (.13%)
Upper Respiratory Tract Disorders	2 (.13%)
Viral Infectious	2 (.13%)
White Blood Cell	2 (.13%)
Abdominal Hernias And Other Abdomin...	1 (.06%)
Adrenal Gland	1 (.06%)
Arteriosclerosis, Stenosis, Vascula...	1 (.06%)
Bone And Joint Therapeutic Procedur...	1 (.06%)
Bone, Calcium, Magnesium And Phosph...	1 (.06%)
Breast	1 (.06%)
Changes In Physical Activity	1 (.06%)
Cranial Nerve Disorders	1 (.06%)
Dental And Gingival Conditions	1 (.06%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Triamterene And Hydrochlorothiazide, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Triamterene And Hydrochlorothiazide is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.